WMHTC today announced a significant transition in its leadership and ownership structure. The current Executive Chair of WMHTC, David Kidney, will be stepping down, marking the end of a pivotal chapter in the organisation’s journey. Effective 1 October 2025, WMHTC will be operated under the stewardship of Medilink Midlands.

This strategic move ensures the continuity of WMHTC’s brand and mission, while aligning its operations with Medilink Midlands’ wider innovation agenda. To support this transition, a new WMHTC Advisory Board will be established to guide strategic direction and maintain stakeholder representation.

David Kidney said:

“The time is right to hand over HTC. We’ve built a strong foundation, and I’m confident that Medilink Midlands will carry forward our vision with integrity and impact. WMHTC has established itself as one of the UK’s leading healthtech clusters by delivering inclusive, innovation-led growth for the region. This collaboration with Medilink Midlands marks a significant step in scaling our impact – strengthening our role as the gateway to healthtech innovation across the West Midlands and East Midlands.”

Professor Martin Levermore MBE DL, Chair of Medilink Midlands, said:

“This transition is a powerful statement of intent – to build a resilient, impactful and globally recognised health and life sciences cluster here in the Midlands. By combining Medilink Midlands’ national connectivity and innovation support expertise with WMHTC’s deep roots in the regional healthtech landscape, we are creating a unified regional platform with the capacity to deliver real economic and health outcomes. Together, we are strengthening our voice, our visibility, and our ability to attract the public and private investment needed to scale.”

Melanie Davidson, CEO of Medilink Midlands, added:

“We thank David for all his hard work and dedication in building WMHTC. He has made a lasting contribution to the healthcare innovation landscape through WMHTC, and we’re honoured to continue that legacy under Medilink Midlands. This transition safeguards WMHTC’s brand and mission, while opening broader opportunities for innovators, investors, and stakeholders across the region and beyond.”

Paul Edwards, Head of Economic Development and Delivery, West Midlands Combined Authority commented:

 “The West Midlands Growth Plan identifies the health and medtech sector as crucial to the future growth of the region. Working with Medilink Midlands and our partners, we’re confident this transition will strengthen both the ecosystem and the story of this thriving cluster.”

For any media queries, please contact:

 Zoe Heather, Marketing Manager, Medilink Midlands marketing@medilinkmidlands.com

Latest Opportunities

Single manufacturer & supplier required for human skin patch: Formulation, manufacture, and packing

Opportunity Company:  Nottingham-based MedTech company Requires: Seeking a single manufacturer and supplier for the formulation,…

Medilink Midlands Job Vacancy - Innovation Adviser

About the job Innovation Adviser – Midlands region – Full time salary £40-45K – Home…

Global Business Innovation Programme: Health & Medical Technologies - Singapore

Innovate UK is inviting ambitious innovative companies to participate in its Global Business Innovation Programme…

Latest News

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep – Helping Gamers…

Kindeva Opens New UK HQ and Manufacturing Site for the Development of Next-Generation Propellants

Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters…

EU MDR/IVDR Revision: A Gateway for Chinese Innovators Entering UK and EU Markets via EFEC

In a significant move for the global medtech landscape, the European Commission has initiated a…